Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
397.50    2.00 (0.51%)
Bid:
390.00
Ask:
405.00
Spread: 15.00 (3.846%)
Market Cap: £190.07m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Additional Investor Presentation

12 Oct 2023 07:00

RNS Number : 8486P
Tristel PLC
12 October 2023
 

Tristel plc

("Tristel" or the "Company")

 

Additional Investor Presentation

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that the Company will deliver a Company Overview presentation at a hybrid event in London hosted by the UK Individual Shareholders' Society (ShareSoc) on Thursday 19 October 2023 and available to ShareSoc members via the link below:

 

https://www.sharesoc.org/sharesoc-walbrook-pr-healthcare-companies-hybrid-event-london-19-october-2023-5pm/

 

Paul Swinney, Chief Executive Officer will deliver an "in-person" presentation which will also be streamed live (and recorded), allowing ShareSoc members to watch virtually.

 

Preliminary results for the year ended 30 June 2023 will be announced on Monday 16 October 2023 and no new material information will be disclosed in the presentation.

 

As previously announced the Company will also provide both an online presentation and in-person presentation open to all interested investors on Monday 16 October 2023. Further details can be found here:

https://tristelgroup.com/wp-content/uploads/2023/09/TSTL-Notice-of-results-FINAL.pdf

 

 

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Chief Financial Officer

 

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

Charlotte Edgar

Mob: 07884 664 686

Cavendish Capital Markets Limited

Tel: 020 7220 0500

Geoff Nash/Charlie Beeson (Corporate Finance)

Sunila de Silva (ECM)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFFIFWFEDSEIS
Date   Source Headline
2nd Oct 202311:50 amRNSHolding(s) in Company
28th Sep 20232:00 pmRNSExercise of Share Options and Total Voting Rights
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM
12th Dec 20227:00 amRNSAGM Statement
2nd Nov 20221:50 pmRNSHolding(s) in Company
25th Oct 20227:00 amRNSAudited Preliminary Results
6th Oct 20229:15 amRNSIssue of Equity
4th Oct 202212:00 pmRNSAppointment of new Company Secretary
4th Oct 20227:00 amRNSNotice of Results & Investor Presentation
29th Sep 20221:00 pmRNSNorth America update
30th Aug 20227:00 amRNSHolding(s) in Company
22nd Jul 20221:05 pmRNSDirector/PDMR Shareholding
21st Jul 202210:15 amRNSHolding(s) in Company
18th Jul 20224:41 pmRNSSecond Price Monitoring Extn
18th Jul 20224:35 pmRNSPrice Monitoring Extension
18th Jul 20227:00 amRNSTrading update and special dividend
30th Jun 20227:00 amRNSDe Novo FDA submission for Tristel Duo ULT
20th Jun 202210:00 amRNSShareholder Open Day & Notice of Trading update
7th Jun 20221:15 pmRNSHolding(s) in Company
4th May 20227:00 amRNSInvestor Presentation
3rd May 202212:30 pmRNSHolding(s) in Company
14th Apr 202212:00 pmRNSIssue of Equity
6th Apr 202212:10 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.